Pfizer Approaches $7.3 Billion Acquisition of Metsera to Expand Obesity Treatment Portfolio

Pfizer is reportedly close to finalizing a $7.3 billion acquisition of Metsera, a company focused on anti-obesity drugs. This strategic move underscores Pfizer's dedication to enhancing its offerings in the growing obesity treatment market, addressing the increasing global demand for effective weight management solutions. The acquisition is expected to strengthen Pfizer's market position and foster innovation in the pharmaceutical sector.